<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01090089</url>
  </required_header>
  <id_info>
    <org_study_id>DSMM XIII</org_study_id>
    <nct_id>NCT01090089</nct_id>
  </id_info>
  <brief_title>Combination of Lenalidomide and Dexamethasone in Treatment of Multiple Myeloma</brief_title>
  <acronym>DSM XIII</acronym>
  <official_title>The Combination of Lenalidomide and Dexamethasone With or Without Intensification by High-dose Melphalan in the Treatment of Multiple Myeloma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ClinAssess GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gesellschaft fur Medizinische Innovation - Hamatologie und Onkologie mbH</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study for elderly myeloma patients lenalidomide plus low-dose dexamethasone until&#xD;
      progression is being compared with age-adjusted tandem high-dose melphalan 140 mg/m²&#xD;
      augmented by induction with 3 cycles of lenalidomide plus low-dose dexamethasone before&#xD;
      transplantation and lenalidomide maintenance after transplantation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 1, 2010</start_date>
  <completion_date type="Anticipated">October 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival (PFS)</measure>
    <time_frame>5 yrs</time_frame>
    <description>To compare the efficacy of both treatment regimens with regard to progression-free survival.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 yrs</time_frame>
    <description>To assess the safety and overall survival of both treatment regimens.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Response (complete response [CR], stringent complete response [sCR], very good partial response [VGPR], partial response [PR] and overall response [CR (incl. sCR)+ VGPR + PR]) according to IMWG criteria</measure>
    <time_frame>5 yrs</time_frame>
    <description>To investigate other efficacy parameters of both treatment regimens</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">348</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>Lenalidomid, PBSCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A1 Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lenalidomid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A2 Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Dexamethasone</intervention_name>
    <description>Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)</description>
    <arm_group_label>Lenalidomid</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lenalidomide, Dexamethasone, PBSCT</intervention_name>
    <description>Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years</description>
    <arm_group_label>Lenalidomid, PBSCT</arm_group_label>
    <other_name>Revlimid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        1. Understand and voluntarily sign an informed consent form. 2. Age 60-75 years at the time&#xD;
        of signing the informed consent form. 3. Able to adhere to the study visit schedule and&#xD;
        other protocol requirements. 4. Symptomatic MM requiring therapy. 5. Measurable monoclonal&#xD;
        protein in serum and/or urine 6. Monoclonal plasma cells in the bone marrow &gt;/= 10% and/or&#xD;
        biopsy-proven plasmacytoma 7. Myeloma-related organ dysfunction, at least one of [C]&#xD;
        Calcium elevation in the serum (&gt; 11.5 mg/dL or &gt; 2.65 mmol/l) [R] Renal insufficiency&#xD;
        (creatinine &gt; 173 μmol/l or &gt; 2 mg/dL) [A] Anemia (Hb &lt; 10 g/dL or 2 g/dL &lt; normal) [B]&#xD;
        Bone lesions or general osteoporosis 8. ECOG PS of &lt;/= 2 ... 9. Laboratory test results&#xD;
        within these ranges within 1 week prior to randomization:&#xD;
&#xD;
          -  ANC &gt;/= 1.0 x 109/L.&#xD;
&#xD;
          -  Platelet count &gt;/= 75 x 109/L or in case of bone marrow infiltration with myeloma&#xD;
             cells &gt;/= 30 x 109/L.&#xD;
&#xD;
          -  Total bilirubin &lt;/= 2 mg/dL.&#xD;
&#xD;
          -  AST (SGOT) and ALT (SGPT) &lt;/= 3 x ULN. 8. Female subjects of childbearing potential&#xD;
             must: o Understand the study drug is expected to have a teratogenic risk&#xD;
&#xD;
             o Agree to use, ..., effective contraception without interruption,...&#xD;
&#xD;
             o Understand that even if she has amenorrhea, she must follow all the advice on&#xD;
             effective contraception.&#xD;
&#xD;
             o She understands the potential consequences of pregnancy and the need to rapidly&#xD;
             consult if there is a risk of pregnancy&#xD;
&#xD;
             o Agree to have a medically supervised pregnancy test ...&#xD;
&#xD;
          -  Male subjects must&#xD;
&#xD;
             o Agree to use condoms throughout study drug therapy, during any dose interruption and&#xD;
             for one week after cessation of study drug therapy ...&#xD;
&#xD;
               -  Agree not to donate semen during study drug therapy and for one week after end of&#xD;
                  study drug therapy.&#xD;
&#xD;
          -  All subjects must&#xD;
&#xD;
               -  Agree to abstain from donating blood while taking study drug therapy and for one&#xD;
                  week following discontinuation of study drug therapy.&#xD;
&#xD;
               -  Agree not to share study drug with another person and to return all unused study&#xD;
                  drug to the investigator.&#xD;
&#xD;
                  9. Disease free of prior malignancies for &gt;/= 5 years with exception of currently&#xD;
                  treated basal cell, squamous cell carcinoma of the skin, or carcinoma &quot;in situ&quot;&#xD;
                  of the cervix or breast.&#xD;
&#xD;
                  10. Able to receive antithrombotic prophylaxis (...). 11. Life-expectancy &gt; 3&#xD;
                  months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Any serious medical condition, laboratory abnormality, or psychiatric illness that&#xD;
             would prevent the subject from signing the ICF.&#xD;
&#xD;
          2. Pregnant or lactating females&#xD;
&#xD;
          3. Any condition, incl. the presence of laboratory abnormalities, which places the&#xD;
             subject at unacceptable risk if he/she were to participate in the study or confounds&#xD;
             the ability to interpret data from the study.&#xD;
&#xD;
          4. Patient currently is enrolled in another clinical research study or has been enrolled&#xD;
             ...within 4 weeks before randomization and/or is receiving an investigational agent&#xD;
             for any reason ...&#xD;
&#xD;
          5. Known hypersensitivity to thalidomide, dexamethasone, or melphalan.&#xD;
&#xD;
          6. The development of erythema nodosum if characterized by a desquamating rash while&#xD;
             taking thalidomide or similar drugs.&#xD;
&#xD;
          7. Any prior use of lenalidomide.&#xD;
&#xD;
          8. Concurrent use of other anti-cancer agents or treatments.&#xD;
&#xD;
          9. Known positive for HIV or active infectious hepatitis, type A, B or C or treponema&#xD;
             pallidum&#xD;
&#xD;
         10. Prior treatment with dexamethasone discontinued because of ≥ grade 3&#xD;
             dexamethasone-related toxicity.&#xD;
&#xD;
         11. Any prior chemotherapy with the exception of a short course of dexamethasone more than&#xD;
             4 weeks before randomization.&#xD;
&#xD;
         12. Immunotherapy or antibody therapy within 8 weeks before randomization.&#xD;
&#xD;
         13. Major surgery within 4 weeks before randomization.&#xD;
&#xD;
         14. Renal failure requiring dialysis.&#xD;
&#xD;
         15. Myocardial infarction within 6 months before randomization, NYHA Class III or IV heart&#xD;
             failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or&#xD;
             electrocardiographic evidence of acute ischemia or active conduction system&#xD;
             abnormalities.&#xD;
&#xD;
         16. Severe pulmonary disease (diffusion capacity &lt; 60% of normal).&#xD;
&#xD;
         17. Treatment for cancer other than MM within 5 years before randomization, with the&#xD;
             exception of basal cell carcinoma or cervical cancer in situ.&#xD;
&#xD;
         18. Cardiac amyloidosis.&#xD;
&#xD;
         19. Poorly controlled hypertension, diabetes mellitus, or other serious medical or&#xD;
             psychiatric illness that could potentially interfere with the completion of treatment&#xD;
             according to the protocol.&#xD;
&#xD;
         20. Any systemic infection requiring treatment.&#xD;
&#xD;
         21. Unability or unwillingness of the patient to receive antithrombotic prophylaxis.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Straka</last_name>
    <role>Principal Investigator</role>
    <affiliation>Agirov Klinik</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Universitätsklinikum Münster</name>
      <address>
        <city>Muenster</city>
        <state>North Rhein Westfallen</state>
        <zip>48149</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agirov Klinik</name>
      <address>
        <city>Berg</city>
        <zip>82335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HELIOS Klinikum Berlin-Buch</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Bielefeld</name>
      <address>
        <city>Bielefeld</city>
        <zip>33611</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Bremen-Mitte</name>
      <address>
        <city>Bremen</city>
        <zip>28177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Erlangen</name>
      <address>
        <city>Erlangen</city>
        <zip>91054</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald -Anstalt öffentlichen Rechts-</name>
      <address>
        <city>Greifswald</city>
        <zip>17475</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona</name>
      <address>
        <city>Hamburg</city>
        <zip>22763</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Schleswig-Holstein</name>
      <address>
        <city>Kiel</city>
        <zip>24105</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stiftungsklinikum Mittelrhein gGmbH</name>
      <address>
        <city>Koblenz</city>
        <zip>56068</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Landshut gemeinnützige GmbH</name>
      <address>
        <city>Landshut</city>
        <zip>84034</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stauferklinikum Schwäbisch Gmünd</name>
      <address>
        <city>Mutlangen</city>
        <zip>73557</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hämato-Onkologische Schwerpunktpraxis</name>
      <address>
        <city>München</city>
        <zip>80331</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Praxis Elisenhof</name>
      <address>
        <city>München</city>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum München Harlaching</name>
      <address>
        <city>München</city>
        <zip>81545</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum rechts der Isar</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26133</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ernst von Bergmann gGmbH</name>
      <address>
        <city>Potsdam</city>
        <zip>14467</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis für Innere Medizin, Hämatologie und Onkologie</name>
      <address>
        <city>Ravensburg</city>
        <zip>88214</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum der Universität Regensburg</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diakonie-Klinikum Stuttgart-Diakonissenkrankenhaus und Paulinenhilfe gGmbH</name>
      <address>
        <city>Stuttgart</city>
        <zip>70176</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Robert-Bosch-Krankenhaus</name>
      <address>
        <city>Stuttgart</city>
        <zip>70376</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Traunstein</name>
      <address>
        <city>Traunstein</city>
        <zip>83278</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HSK Dr. Horst-Schmidt-Kliniken gmbh</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>March 18, 2010</study_first_submitted>
  <study_first_submitted_qc>March 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 19, 2010</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>BB 1101</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

